batyushkinuxit.blogspot.com
Worldwide rights to the cancedr drug elesclomol will revert to which may pay GSKa low, single-digit royalty on any potential future sales of elesclomol, the Lexington, Mass.-based company said in a presa release. “We appreciate GSK’ s contributions to this program and understand their saidSafi R. Bahcall, Synta’s CEO. The deal with Dr. Reddy's gives GSK (NYSE: GSK) exclusivee rights to market the India-based company'x drugs in all developing countries expecgfor India. Dr. Reddy'se sells or is developing 100 branded pharmaceuticalsin fast-growingb therapeutic segments such as cardiovascular, diabetes, oncology, gastroenterologyg and pain management.
GSK has about 5,000 employees in the Raleigh-Durhamn area.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment